Abbott Laboratories $ABT Shares Bought by DMKC Advisory Services LLC

DMKC Advisory Services LLC grew its stake in Abbott Laboratories (NYSE:ABT) by 22.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,088 shares of the healthcare product maker’s stock after buying an additional 7,821 shares during the period. DMKC Advisory Services LLC’s holdings in Abbott Laboratories were worth $3,910,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Nia Impact Advisors LLC lifted its position in Abbott Laboratories by 2.2% in the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after acquiring an additional 79 shares during the last quarter. Clayton Financial Group LLC grew its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock worth $779,000 after purchasing an additional 84 shares during the last quarter. Raleigh Capital Management Inc. increased its position in shares of Abbott Laboratories by 3.9% during the fourth quarter. Raleigh Capital Management Inc. now owns 2,287 shares of the healthcare product maker’s stock worth $287,000 after purchasing an additional 85 shares in the last quarter. Riggs Asset Managment Co. Inc. lifted its holdings in shares of Abbott Laboratories by 9.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock valued at $140,000 after purchasing an additional 88 shares during the last quarter. Finally, GHP Investment Advisors Inc. lifted its holdings in shares of Abbott Laboratories by 0.3% in the 4th quarter. GHP Investment Advisors Inc. now owns 29,411 shares of the healthcare product maker’s stock valued at $3,685,000 after purchasing an additional 92 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $105.68 on Thursday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The stock has a market cap of $182.86 billion, a PE ratio of 34.20, a P/E/G ratio of 2.04 and a beta of 0.59. The stock has a fifty day moving average price of $94.63 and a 200 day moving average price of $100.07. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ABT shares. Stifel Nicolaus reduced their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Wells Fargo & Company raised their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Piper Sandler restated an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Robert W. Baird started coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price for the company. Finally, Evercore decreased their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $118.17.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.